Viking Therapeutics surges on positive VK2735 weight-loss trial data
+35.67% to $40.85 from $30.11
What moved VKTX
- Viking Therapeutics reported that its dual GLP-1/GIP obesity candidate VK2735 produced a 22% placebo-adjusted weight loss at 33 weeks on the 17.5 mg dose in a Phase 2 study, surpassing a 20% efficacy benchmark investors had been watching for.
- In the trial’s 12-week maintenance phase, patients who switched from weekly to every-other-week dosing retained up to 97% of their prior weight loss, while those on monthly dosing preserved up to 90%.
- Truist analyst Gregory Renza described the results as a “best-case scenario” for the drug.
- The company said the data support its plan to begin Phase III trials of VK2735 by year-end.
Sources: GuruFocus · Stocktwits · Yahoo Finance